文献速递胸部肿瘤

PD-1抑制剂联合化疗新辅助治疗Ⅱ~Ⅲ期非小细胞肺癌的疗效与安全性

[The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2020-01-01

该研究纳入13例Ⅱ~Ⅲ期NSCLC患者,接受PD-1单抗联合化疗新辅助治疗,2周期后评价。ORR为61.5%,DCR为100%,分期下降率61.5%,手术切除率38.5%,MPR率60.0%,CPR率20.0%。主要3~4级不良反应为中性粒细胞减少(38.5%)和白细胞减少(23.1%),未见明显免疫相关毒性。

要点

  • PD-1单抗联合化疗新辅助治疗Ⅱ~Ⅲ期NSCLC的ORR达61.5%,DCR达100%。
  • 手术切除患者中MPR率60.0%,CPR率20.0%,围手术期安全耐受。
  • 主要3~4级毒性为中性粒细胞减少(38.5%)和白细胞减少(23.1%)。

核心结论

  • 免疫联合化疗作为Ⅱ~Ⅲ期NSCLC新辅助治疗有效、低毒,围手术期安全且MPR率高,是值得进一步探索的方案。

研究设计与样本

  • 回顾性分析中国医学科学院肿瘤医院内科13例Ⅱ~Ⅲ期NSCLC患者,接受PD-1单抗联合化疗新辅助治疗,21天为一周期,2周期后评价疗效与安全性。

主要发现

  • 截至2019年12月2日,全组ORR为61.5%(95%CI 30.9%-92.1%),DCR为100%。
  • 治疗后分期下降率为61.5%(8/13)。
  • 手术切除率为38.5%(5/13),其中MPR率为60.0%(3/5),CPR率为20.0%(1/5)。
  • 主要3~4级不良反应为中性粒细胞减少(38.5%)和白细胞减少(23.1%),未见明显免疫相关不良反应。

临床怎么用

  • 对于可手术的Ⅱ~Ⅲ期NSCLC患者,PD-1单抗联合化疗可作为新辅助治疗选择,需关注骨髓抑制毒性并评估围手术期安全性。

局限性

  • 样本量小(13例),为单中心回顾性分析,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the safety and therapeutic effect of programmed death 1 (PD-1) antibody combined with chemotherapy as a neoadjuvant therapy for patients with stage Ⅱ to Ⅲ non-small cell lung cancer (NSCLC). Methods: Thirteen patients, who had been diagnosed as stage Ⅱ-Ⅲ NSCLC and received PD-1 inhibitor plus chemotherapy as a neoadjuvant treatment in National Cancer Center/Cancer Hospital were recruited. The patients received consecutive neoadjuvant chemotherapy for 21 days as a cycle and the therapeutic efficacy was evaluated after two cycles. Results: At the last time of follow-up on December 2, 2019, the objective response rate (ORR) and disease control rate (DCR) of these patients were 61.5% (95% CI 30.9%-92.1%) and 100%, respectively. The downregulation rate of disease stage was 61.5% (8/13). The resectable rate was 38.5% (5/13), among them, the major pathologic response (MPR) was 60.0% (3/5) and the complete pathologic response (CPR) was 20.0% (1/5). The neoadjuvant chemotherapy displayed a low incidence of adverse reaction. The main grade 3 to 4 toxicities were neutropenia (38.5%) and leukopenia (23.1%). There was no significant immune-related toxicity. The safety and tolerability of perioperative period of patients underwent resection were promising. Conclusions: Immunotherapy combined with chemotherapy as a neoadjuvant treatment is an effective, low-toxicity treatment manner, which has perioperative safety and high rate of MPR for patients with resectable NSCLC. It is a promising treatment option for patients with stage Ⅱ to Ⅲ NSCLC. 目的: 探讨程序性细胞死亡蛋白1(PD-1)单抗联合化疗在Ⅱ~Ⅲ期非小细胞肺癌(NSCLC)术前新辅助治疗中的疗效和安全性。 方法: 分析中国医学科学院肿瘤医院内科13例Ⅱ~Ⅲ期NSCLC患者接受PD-1单抗联合化疗作为新辅助治疗的疗效和安全性,治疗方案为每21 d为1个治疗周期,2个周期后评价患者的疗效和安全性。 结果: 截至2019年12月2日,全组患者影像学评价客观有效率(ORR)和疾病控制率(DCR)分别为61.5%和100%。治疗后分期下降率为61.5%(8/13)。手术切除率为38.5%(5/13),显著病理缓解(MPR)率为60.0%(3/5),完全病理缓解率为20.0%(1/5)。治疗相关的不良反应发生率低,主要的3~4级不良反应为中性粒细胞减少(38.5%)和白细胞减少(23.1%),未见明显免疫相关不良反应。接受手术的患者围手术期的安全性和耐受性良好。 结论: 对于Ⅱ~Ⅲ期NSCLC患者,免疫治疗联合化疗作为新辅助治疗具有疗效好、不良反应发生率低、围手术期安全性好、MPR率高等特点。免疫治疗联合化疗是Ⅱ~Ⅲ期NSCLC值得进一步探索的新辅助治疗方案。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Liu YT, Gao YS, Mao YS, et al. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32575944. doi:10.3760/cma.j.cn112152-20200213-00087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。